Whole Exon Deletion in the GFAP Gene Is a Novel Molecular Mechanism Causing Alexander Disease

Lydia Green, Ian R. Berry, Anne Marie Childs, Helen Mccullagh, Sandhya Jose, Dan Warren, Ian Craven, Nick Camm, Katrina Prescott, Marjo S. van der Knaap, Eamonn Sheridan, John H. Livingston

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Alexander disease (AD) is a leukodystrophy caused by heterozygous mutations in the gene encoding the glial fibrillary acidic protein (GFAP). Currently, de novo heterozygous missense mutations in the GFAP gene are identified in over 95% of patients with AD. However, patients with biopsy-proven AD have been reported in whom no GFAP mutation has been identified. We report identical twin boys presenting in infancy with seizures and developmental delay in whom MR appearances were suggestive of AD with the exception of an unusual, bilateral, arc of calcification at the frontal white–gray junction. Initial mutation screening of the GFAP gene did not identify a mutation. Whole exome sequencing in both brothers revealed a de novo heterozygous in-frame deletion of the whole of exon 5 of the GFAP gene. Mutations in the GFAP gene are thought to result in a toxic effect of mutant GFAP disrupting the formation of the normal intermediate filament network and resulting in Rosenthal fiber formation, which has hitherto not been linked to exonic scale copy number variants in GFAP . Further studies on mutation negative AD patients are warranted to determine whether a similar mechanism underlies their disease.

Original languageEnglish
Pages (from-to)118-122
Number of pages5
JournalNeuropediatrics
Volume49
Issue number2
DOIs
Publication statusPublished - 1 Apr 2018

Cite this

Green, L., Berry, I. R., Childs, A. M., Mccullagh, H., Jose, S., Warren, D., ... Livingston, J. H. (2018). Whole Exon Deletion in the GFAP Gene Is a Novel Molecular Mechanism Causing Alexander Disease. Neuropediatrics, 49(2), 118-122. https://doi.org/10.1055/s-0037-1608921
Green, Lydia ; Berry, Ian R. ; Childs, Anne Marie ; Mccullagh, Helen ; Jose, Sandhya ; Warren, Dan ; Craven, Ian ; Camm, Nick ; Prescott, Katrina ; van der Knaap, Marjo S. ; Sheridan, Eamonn ; Livingston, John H. / Whole Exon Deletion in the GFAP Gene Is a Novel Molecular Mechanism Causing Alexander Disease. In: Neuropediatrics. 2018 ; Vol. 49, No. 2. pp. 118-122.
@article{62faa8d6af8445d2816d42ec3e9e2ba1,
title = "Whole Exon Deletion in the GFAP Gene Is a Novel Molecular Mechanism Causing Alexander Disease",
abstract = "Alexander disease (AD) is a leukodystrophy caused by heterozygous mutations in the gene encoding the glial fibrillary acidic protein (GFAP). Currently, de novo heterozygous missense mutations in the GFAP gene are identified in over 95{\%} of patients with AD. However, patients with biopsy-proven AD have been reported in whom no GFAP mutation has been identified. We report identical twin boys presenting in infancy with seizures and developmental delay in whom MR appearances were suggestive of AD with the exception of an unusual, bilateral, arc of calcification at the frontal white–gray junction. Initial mutation screening of the GFAP gene did not identify a mutation. Whole exome sequencing in both brothers revealed a de novo heterozygous in-frame deletion of the whole of exon 5 of the GFAP gene. Mutations in the GFAP gene are thought to result in a toxic effect of mutant GFAP disrupting the formation of the normal intermediate filament network and resulting in Rosenthal fiber formation, which has hitherto not been linked to exonic scale copy number variants in GFAP . Further studies on mutation negative AD patients are warranted to determine whether a similar mechanism underlies their disease.",
keywords = "Alexander disease, GFAP gene, intracranial calcification, leukodystrophy, whole exon deletion",
author = "Lydia Green and Berry, {Ian R.} and Childs, {Anne Marie} and Helen Mccullagh and Sandhya Jose and Dan Warren and Ian Craven and Nick Camm and Katrina Prescott and {van der Knaap}, {Marjo S.} and Eamonn Sheridan and Livingston, {John H.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1055/s-0037-1608921",
language = "English",
volume = "49",
pages = "118--122",
journal = "Neuropediatrics",
issn = "0174-304X",
publisher = "Hippokrates Verlag GmbH",
number = "2",

}

Green, L, Berry, IR, Childs, AM, Mccullagh, H, Jose, S, Warren, D, Craven, I, Camm, N, Prescott, K, van der Knaap, MS, Sheridan, E & Livingston, JH 2018, 'Whole Exon Deletion in the GFAP Gene Is a Novel Molecular Mechanism Causing Alexander Disease' Neuropediatrics, vol. 49, no. 2, pp. 118-122. https://doi.org/10.1055/s-0037-1608921

Whole Exon Deletion in the GFAP Gene Is a Novel Molecular Mechanism Causing Alexander Disease. / Green, Lydia; Berry, Ian R.; Childs, Anne Marie; Mccullagh, Helen; Jose, Sandhya; Warren, Dan; Craven, Ian; Camm, Nick; Prescott, Katrina; van der Knaap, Marjo S.; Sheridan, Eamonn; Livingston, John H.

In: Neuropediatrics, Vol. 49, No. 2, 01.04.2018, p. 118-122.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Whole Exon Deletion in the GFAP Gene Is a Novel Molecular Mechanism Causing Alexander Disease

AU - Green, Lydia

AU - Berry, Ian R.

AU - Childs, Anne Marie

AU - Mccullagh, Helen

AU - Jose, Sandhya

AU - Warren, Dan

AU - Craven, Ian

AU - Camm, Nick

AU - Prescott, Katrina

AU - van der Knaap, Marjo S.

AU - Sheridan, Eamonn

AU - Livingston, John H.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Alexander disease (AD) is a leukodystrophy caused by heterozygous mutations in the gene encoding the glial fibrillary acidic protein (GFAP). Currently, de novo heterozygous missense mutations in the GFAP gene are identified in over 95% of patients with AD. However, patients with biopsy-proven AD have been reported in whom no GFAP mutation has been identified. We report identical twin boys presenting in infancy with seizures and developmental delay in whom MR appearances were suggestive of AD with the exception of an unusual, bilateral, arc of calcification at the frontal white–gray junction. Initial mutation screening of the GFAP gene did not identify a mutation. Whole exome sequencing in both brothers revealed a de novo heterozygous in-frame deletion of the whole of exon 5 of the GFAP gene. Mutations in the GFAP gene are thought to result in a toxic effect of mutant GFAP disrupting the formation of the normal intermediate filament network and resulting in Rosenthal fiber formation, which has hitherto not been linked to exonic scale copy number variants in GFAP . Further studies on mutation negative AD patients are warranted to determine whether a similar mechanism underlies their disease.

AB - Alexander disease (AD) is a leukodystrophy caused by heterozygous mutations in the gene encoding the glial fibrillary acidic protein (GFAP). Currently, de novo heterozygous missense mutations in the GFAP gene are identified in over 95% of patients with AD. However, patients with biopsy-proven AD have been reported in whom no GFAP mutation has been identified. We report identical twin boys presenting in infancy with seizures and developmental delay in whom MR appearances were suggestive of AD with the exception of an unusual, bilateral, arc of calcification at the frontal white–gray junction. Initial mutation screening of the GFAP gene did not identify a mutation. Whole exome sequencing in both brothers revealed a de novo heterozygous in-frame deletion of the whole of exon 5 of the GFAP gene. Mutations in the GFAP gene are thought to result in a toxic effect of mutant GFAP disrupting the formation of the normal intermediate filament network and resulting in Rosenthal fiber formation, which has hitherto not been linked to exonic scale copy number variants in GFAP . Further studies on mutation negative AD patients are warranted to determine whether a similar mechanism underlies their disease.

KW - Alexander disease

KW - GFAP gene

KW - intracranial calcification

KW - leukodystrophy

KW - whole exon deletion

UR - http://www.scopus.com/inward/record.url?scp=85038615891&partnerID=8YFLogxK

U2 - 10.1055/s-0037-1608921

DO - 10.1055/s-0037-1608921

M3 - Article

VL - 49

SP - 118

EP - 122

JO - Neuropediatrics

JF - Neuropediatrics

SN - 0174-304X

IS - 2

ER -